Seagen’s megahit Tukysa has now shown evidence for the treatment of colorectal cancer after previously being successful as a treatment for breast cancer. The biotech firm released successful results of Tukysa 2 Mountaineer trial investigation when combined with chemotherapy on the patients with metastatic colorectal cancer. 117 subjects were involved in research and 38% of them experienced partial or complete responses, which allowed the trial to meet its major objective. The firm informed that this medicine did not show major side effects, for the most part. Seagen is ready to submit an application to the FDA regarding a new drug.
Read More from FiercePharma